SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Calidi Biotherapeutics, Inc. (CLDI) News

Follow Calidi Biotherapeutics, Inc. (CLDI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol CLDI Asset equity Sector Markets 90 days 7 Last 0.5559 Updated Sep 25, 2026, 09:35 PM UTC Open live news feed Open CLDI chart & news
L Calidi Biotherapeutics Received Notice of Noncompliance On September 21, 2026, the company received a notice from NYSE American that it is not in compliance with Section 1003(a)(ii) due to stockholders' equity of $3.1 million versus the $4.0 million requirement and losses in NEWS | Sep 25, 2026, 09:35 PM UTC L Calidi Biotherapeutics, Inc. (CLDI) Gets NYSE American Equity Deficiency Notice Calidi Biotherapeutics received an NYSE American notice for non-compliance with stockholders’ equity requirements and must submit a plan by Oct. 21, 2026 to regain compliance by Mar. 21, 2028, or face potential delisting NEWS | Sep 25, 2026, 09:02 PM UTC L Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announ NEWS | Sep 25, 2026, 09:02 PM UTC M Calidi Biotherapeutics raises $1.2M via registered direct offering Calidi Biotherapeutics sold 1,025,640 common shares at $1.17 per share, generating about $1.2 million in gross proceeds. The offering closed September 21, 2026. EQUITY | Sep 22, 2026, 09:03 PM UTC L CLDI - Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering CLDI - Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering NEWS | Sep 17, 2026, 01:11 PM UTC L Calidi Biotherapeutics to participate in H.C. Wainwright 28th conference Calidi Biotherapeutics Inc. (NYSE American: CLDI) said it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. EQUITY | Sep 08, 2026, 12:07 PM UTC L CLDI - Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference CLDI - Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference EQUITY | Sep 08, 2026, 12:00 PM UTC L Calidi Biotherapeutics reports Q2 2026 financial results Calidi Biotherapeutics (CLDI) reports its second quarter 2026 financial results and recent business highlights. EARNINGS | Aug 13, 2026, 08:30 PM UTC L CSAI, NEXR, CLDI, OFAL Split CSAI, NEXR, CLDI, OFAL undergo reverse stock splits EQUITY | Jul 30, 2026, 09:19 PM UTC M CSAI, NEXR, CLDI, OFAL Split Stock splits for CSAI, NEXR, CLDI, OFAL EQUITY | Jul 30, 2026, 02:56 PM UTC L CLDI - Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Asso CLDI - Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference EQUITY | Jul 27, 2026, 12:00 PM UTC H Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Shares of Crown Holdings Inc (NYSE: CCK ) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY26 adjusted EPS guidance above estimates. Cro EARNINGS | Jul 21, 2026, 09:11 AM UTC M CLDI Presents T-Cell Data Calidi Biotherapeutics Presents Data On Its Approach Of Simultaneously Activating T-cells While Inducing Expression Of T-Cell Engagers Specifically In Situ In Tumor Microenvironment EQUITY | Jun 24, 2026, 12:07 PM UTC M CLDI Presents CLD-501 Data Calidi Biotherapeutics presents new data on CLD-501, its in situ T-cell engager candidate targeting TROP-2 EQUITY | Jun 24, 2026, 12:00 PM UTC L CLDI Appoints Corsee Sanders Calidi Biotherapeutics appoints Corsee Sanders, Ph.D., to its Board of Directors, bringing over three decades of biopharmaceutical development experience EQUITY | Jun 23, 2026, 12:01 PM UTC